EUVIMEDEUVIMED entdecken
Crossref

Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice

Min-Min Gong, Meng-di Zhu, Wen-Bin Wu, Hui Dong, Fan Wu, Jing Gong, Fu-Er Lu

Chinese Journal of Integrative Medicine · 2025

DOI: 10.1007/s11655-024-3919-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chinese Journal of Integrative Medicine, 2025. Verfasst von Min-Min Gong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technol…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Interleukin-17, Drugs, Chinese Herbal. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To identify the underlying molecular mechanism of Modified Hu-Lu-Ba-Wan (MHW) in alleviating renal lesions in mice with diabetic kidney disease (DKD). METHODS: The db/db mice were divided into model group and MHW group according to a random number table, while db/m mice were settled as the control group (n=8 per group). The control and model groups were gavaged daily with distilled water [10 mL/(kg·d)], and the MHW group was treated with MHW [17.8 g/(kg·d)] for 6 weeks. After MHW administration for 6 weeks, indicators associated with glucolipid metabolism and urinary albumin were tested. Podocytes were observed by transmission electron microscopy. Kidney transcriptomics was performed after confirming therapeutic effects of MHW on DKD mice. The relevant target of MHW' effect in DKD was further determined by enzyme-linked immunosorbent assay, Western blot analysis, immunohistochemistry, and immunofluorescence staining. RESULTS: Compared with the model group, MHW improved glucose and lipid metabolism (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesInterleukin-17Drugs, Chinese HerbalAnimalsMaleKidneyPodocytesMiceAlbuminuriaLipid MetabolismMice, Inbred C57BL

Stichwörter der Autor:innen

Chinese medicineModified Hu-Lu-Ba-Wandiabetic kidney diseaseearly fibrosisinflammationinterleukin-17A

Substanzen

Interleukin-17Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. felutjh88@163.com.

Zitieren

APA

Gong, M. M., Zhu, M. D., Wu, W. B., Dong, H., Wu, F., Gong, J., & Lu, F. E. (2025). Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-3919-x

Vancouver

Gong MM, Zhu MD, Wu WB, Dong H, Wu F, Gong J, et al. Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice. Chinese Journal of Integrative Medicine. 2025. doi:10.1007/s11655-024-3919-x

BibTeX
@article{Gong2025,
  author = {Gong, Min-Min and Zhu, Meng-di and Wu, Wen-Bin and Dong, Hui and Wu, Fan and Gong, Jing and Lu, Fu-Er},
  title = {Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2025},
  doi = {10.1007/s11655-024-3919-x}
}
Kostenlos starten →